Ethereum Startup AgoraLend Opens Fresh Fundraise After Oversubscribed $300,000 Round Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
– Positive interim data through cohort five for the ReSPECT™ Phase 1 clinical trial in…
GenMark ePlex® RP2 Panel Predicted to Detect Known SARS-CoV-2 Variants Currently in Circulation Based on in silico Analysis
CARLSBAD, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) — GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading…
Opiant Pharmaceuticals to Report Fourth Quarter 2020 Financial Results and Host Conference Call and Webcast on March 4, 2021
SANTA MONICA, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a…
Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN)
–Dermatological indication characterized by chronic, intensely itchy nodules; mast cell activation believed to play an…
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with…
MatriSys Announces Positive Results From a Phase I Study of MSB-0221 for the Topical Treatment of Atopic Dermatitis
– Study Reveals the Potential of Beneficial Bacteria to Treat Chronic Skin Diseases – LA…
Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial Results
Key Opinion Leader Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates,…
Sanofi: Information concerning the total number of voting rights and shares – January 2021
Information concerning the total number of voting rights and shares, provided pursuant to article L….
Axiom Presents “Innovating Direct-to-Patient Trials: How to use effective eClinical Solutions to enhance the success of your clinical studies” at Outsourcing in Clinical Trials West Coast 2021
SAN FRANCISCO, Feb. 22, 2021 (GLOBE NEWSWIRE) — Axiom Real-Time Metrics (“Axiom”), premier provider of…
Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D., to Board of Directors
REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) (“Company”) announced today…
Transactions under Novozymes’ stock buyback program
Please read the full announcement in the attached PDF Attachment 2021_09_Stock_Buybackprogram
Tricida to Report Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call and Webcast on Thursday, February 25, 2021
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) — Tricida, Inc. (Nasdaq: TCDA) today announced…
Myovant Sciences to Present at Upcoming Investor Conferences
BASEL, Switzerland, Feb. 22, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused…
Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting
WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) — Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage…
Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA
FREMONT, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company,…
Vericel to Present at the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced…
PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing COVID-19 Vaccine
Brazilian-based Blanver brings depth of expertise in development and commercialization of innovative pharmaceuticals across Latin…
Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease
– Two Upcoming Phase 3 Studies and a Previously Completed Phase 2 Program Support a New…